Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
21 oct. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
20 sept. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
– Ms. Corzo brings a 25+ year successful track record in biopharma, excelling in oncology drug development with Takeda, Sanofi Genzyme, and Eli Lilly – BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE...
Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
14 sept. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, presented a Company overview...
Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
13 sept. 2021 06h00 HE
|
Matinas BioPharma Holdings, Inc.
– Step-down therapy with MAT2203 achieved effective clearance of fungal organisms; Mean Early Fungicidal Activity (EFA) was 0.38, exceeding the prespecified primary endpoint threshold target of...
Matinas BioPharma Announces Issuance of U.S. Patent Protecting MAT2203 to Treat or Prevent Cryptococcus Infections
16 août 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma Reports Second Quarter 2021 Financial Results and Operational Highlights
10 août 2021 06h31 HE
|
Matinas BioPharma Holdings, Inc.
– Enrollment complete in second cohort of EnACT study of MAT2203 (oral amphotericin B) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) review of safety and efficacy data from...
Matinas BioPharma to Participate in BTIG Virtual Biotechnology Conference
03 août 2021 07h30 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to...
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2021 Financial and Operational Results on August 10, 2021
27 juil. 2021 07h00 HE
|
Matinas BioPharma Holdings, Inc.
BEDMINSTER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of...
Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021
20 mai 2021 08h00 HE
|
Matinas BioPharma Holdings, Inc.
Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs David R. Boulware, M.D., MPH, Professor of Medicine, Infectious Disease and...
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
10 mai 2021 06h30 HE
|
Matinas BioPharma Holdings, Inc.
– Enrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from...